Pharmacokinetics and derivation of an anticancer dosing regimen for the novel anti-cancer agent isobutyl-deoxynyboquinone (IB-DNQ), a NQO1 bioactivatable molecule, in the domestic felid species

Investigational New Drugs

Volumn 35, Issue 2, 2017, Pages 134-144

  Lundberg, Alycen P ^a   Francis, Joshua M ^a   Pajak, Malgorzata ^a   Parkinson, Elizabeth I ^a   Wycislo, Kathryn L ^a   Rosol, Thomas J ^b   Brown, Megan E ^b   London, Cheryl A ^b   Dirikolu, Levent ^c   Hergenrother, Paul J ^a   Fan, Timothy M ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

Comparative oncology; Deoxynyboquinone; Feline oral squamous cell carcinoma; Novel anti cancer agent; NQO1; lapachone

Indexed keywords

ANTINEOPLASTIC AGENT; ISOBUTYLDEOXYNYBOQUINONE; QUINONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG; 8-OXO-7-HYDRODEOXYGUANOSINE; DEOXYGUANOSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD TOXICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; FEASIBILITY STUDY; FELIDAE; FEMALE; HYPERSALIVATION; IMMORTALIZED CELL LINE; IN VITRO STUDY; IN VIVO STUDY; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; OXIDATIVE STRESS; PREDICTION; PROTEIN EXPRESSION; TACHYPNEA; TISSUE MICROARRAY; A-549 CELL LINE; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; CAT; CELL SURVIVAL; DRUG EFFECTS; HEK293 CELL LINE; HUMAN; METABOLISM; MOUTH TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

A549 CELLS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CATS; CELL LINE, TUMOR; CELL SURVIVAL; DEOXYGUANOSINE; FEMALE; HEK293 CELLS; HUMANS; MOUTH NEOPLASMS; NAD(P)H DEHYDROGENASE (QUINONE); QUINONES;

EID: 85006166035     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-016-0414-z     Document Type: Article

References (54)

1. Pavet V, Portal MM, Moulin JC, Herbrecht R, Gronemeyer H (2011) Towards novel paradigms for cancer therapy. Oncogene 30(1):1–20
2. Kundu SK, Nestor M (2012) Targeted therapy in head and neck cancer. Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine 33(3):707–721
3. Pink JJ, Planchon SM, Tagliarino C, Varnes ME, Siegel D, Boothman DA (2000) NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity. J Biol Chem 275(8):5416–5424
4. Danson S, Ward TH, Butler J, Ranson M (2004) DT-diaphorase: a target for new anticancer drugs. Cancer Treat Rev 30(5):437–449
5. Siegel D, Yan C, Ross D (2012) NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. Biochem Pharmacol 83(8):1033–1040
6. Parkinson EI, Hergenrother PJ (2015) Deoxynyboquinones as NQO1-activated cancer therapeutics. Acc Chem Res 48(10):2715–2723
7. Schlager JJ, Powis G (1990) Cytosolic NAD(P)H:(quinone-acceptor) oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. Int J Cancer 45(3):403–409
8. Malkinson AM, Siegel D, Forrest GL, Gazdar AF, Oie HK, Chan DC, Bunn PA, Mabry M, Dykes DJ, Harrison SD et al (1992) Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin Cl. Cancer Res 52(17):4752–4757
9. Smitskamp-Wilms E, Giaccone G, Pinedo HM, van der Laan BF, Peters GJ (1995) DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents? Br J Cancer 72(4):917–921
10. Marin A, de Lopez Cerain A, Hamilton E, Lewis AD, Martinez-Penuela JM, Idoate MA, Bello J (1997) DT-diaphorase and cytochrome B5 reductase in human lung and breast tumours. Br J Cancer 76(7):923–929
11. Siegel D, Ross D (2000) Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues. Free Radic Biol Med 29(3–4):246–253
12. Kolesar JM, Pritchard SC, Kerr KM, Kim K, Nicolson MC, McLeod H (2002) Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue. Int J Oncol 21(5):1119–1124
13. Bey EA, Bentle MS, Reinicke KE, Dong Y, Yang CR, Girard L, Minna JD, Bornmann WG, Gao J, Boothman DA (2007) An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone. Proc Natl Acad Sci U S A 104(28):11832–11837
14. Li Z, Zhang Y, Jin T, Men J, Lin Z, Qi P, Piao Y, Yan G (2015) NQO1 protein expression predicts poor prognosis of non-small cell lung cancers. BMC Cancer 15:207
15. Logsdon CD, Simeone DM, Binkley C, Arumugam T, Greenson JK, Giordano TJ, Misek DE, Kuick R, Hanash S (2003) Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 63(10):2649–2657
16. Lewis AM, Ough M, Hinkhouse MM, Tsao MS, Oberley LW, Cullen JJ (2005) Targeting NAD(P)H:quinone oxidoreductase (NQO1) in pancreatic cancer. Mol Carcinog 43(4):215–224
17. Lyn-Cook BD, Yan-Sanders Y, Moore S, Taylor S, Word B, Hammons GJ (2006) Increased levels of NAD(P)H: quinone oxidoreductase 1 (NQO1) in pancreatic tissues from smokers and pancreatic adenocarcinomas: a potential biomarker of early damage in the pancreas. Cell Biol Toxicol 22(2):73–80
18. Li LS, Reddy S, Lin ZH, Liu S, Park H, Chun SG, Bornmann WG, Thibodeaux J, Yan J, Chakrabarti G et al (2016) NQO1-mediated tumor-selective lethality and Radiosensitization for head and neck cancer. Mol Cancer Ther 15(7):1757–1767
19. Parkinson EI, Bair JS, Cismesia M, Hergenrother PJ (2013) Efficient NQO1 substrates are potent and selective anticancer agents. ACS Chem Biol 8(10):2173–2183
20. Park HJ, Ahn KJ, Ahn SD, Choi E, Lee SW, Williams B, Kim EJ, Griffin R, Bey EA, Bornmann WG et al (2005) Susceptibility of cancer cells to beta-lapachone is enhanced by ionizing radiation. Int J Radiat Oncol Biol Phys 61(1):212–219
21. Terai K, Dong GZ, Oh ET, Park MT, Gu Y, Song CW, Park HJ (2009) Cisplatin enhances the anticancer effect of beta-lapachone by upregulating NQO1. Anti-Cancer Drugs 20(10):901–909
22. Ahn KJ, Lee HS, Bai SK, Song CW (2013) Enhancement of radiation effect using beta-lapachone and underlying mechanism. Radiation Oncology Journal 31(2):57–65
23. Bermejo M, Mangas-Sanjuan V, Gonzalez-Alvarez I, Gonzalez-Alvarez M (2016) Enhancing oral absorption of beta-lapachone: progress till date. Eur J Drug Metab Pharmacokinet. doi:10.1007/s13318-016-0369-7
24. Blanco E, Bey EA, Dong Y, Weinberg BD, Sutton DM, Boothman DA, Gao J (2007) Beta-lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells. Journal of Controlled Release: Official Journal of the Controlled Release Society 122(3):365–374
25. Blanco E, Bey EA, Khemtong C, Yang SG, Setti-Guthi J, Chen H, Kessinger CW, Carnevale KA, Bornmann WG, Boothman DA et al (2010) Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy. Cancer Res 70(10):3896–3904
26. Ma X, Huang X, Moore Z, Huang G, Kilgore JA, Wang Y, Hammer S, Williams NS, Boothman DA, Gao J (2015) Esterase-activatable beta-lapachone prodrug micelles for NQO1-targeted lung cancer therapy. Journal of Controlled Release: Official Journal of the Controlled Release Society 200:201–211
27. Zhang L, Chen Z, Yang K, Liu C, Gao J, Qian F (2015) Beta-lapachone and paclitaxel combination micelles with improved drug encapsulation and therapeutic synergy as novel nanotherapeutics for NQO1-targeted cancer therapy. Mol Pharm 12(11):3999–4010
28. Bair JS, Palchaudhuri R, Hergenrother PJ (2010) Chemistry and biology of deoxynyboquinone, a potent inducer of cancer cell death. J Am Chem Soc 132(15):5469–5478
29. Mak IW, Evaniew N, Ghert M (2014) Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res 6(2):114–118
30. Kamb A (2005) What's wrong with our cancer models? Nat Rev Drug Discov 4(2):161–165
31. Talmadge JE, Singh RK, Fidler IJ, Raz A (2007) Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol 170(3):793–804
32. Mestas J, Hughes CC (2004) Of mice and not men: differences between mouse and human immunology. J Immunol 172(5):2731–2738
33. Richmond A, Su Y (2008) Mouse xenograft models vs GEM models for human cancer therapeutics. Disease Models & Mechanisms 1(2–3):78–82
34. Khanna C, Lindblad-Toh K, Vail D, London C, Bergman P, Barber L, Breen M, Kitchell B, McNeil E, Modiano JF et al (2006) The dog as a cancer model. Nat Biotechnol 24(9):1065–1066
35. Paoloni M, Khanna C (2008) Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 8(2):147–156
36. LeBlanc AK, Breen M, Choyke P, Dewhirst M, Fan TM, Gustafson DL, Helman LJ, Kastan MB, Knapp DW, Levin WJ et al (2016) Perspectives from man's best friend: National Academy of Medicine's workshop on comparative oncology. Sci Transl Med 8(324):324ps5
37. Paoloni M, Davis S, Lana S, Withrow S, Sangiorgi L, Picci P, Hewitt S, Triche T, Meltzer P, Khanna C (2009) Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics 10:625
38. Angstadt AY, Motsinger-Reif A, Thomas R, Kisseberth WC, Guillermo Couto C, Duval DL, Nielsen DM, Modiano JF, Breen M (2011) Characterization of canine osteosarcoma by array comparative genomic hybridization and RT-qPCR: signatures of genomic imbalance in canine osteosarcoma parallel the human counterpart. Genes Chromosom Cancer 50(11):859–874
39. Breen M, Modiano JF (2008) Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans--man and his best friend share more than companionship. Chromosome Research: an International Journal on the Molecular, Supramolecular and Evolutionary Aspects of Chromosome Biology 16(1):145–154
40. Wypij JM (2013) A naturally occurring feline model of head and neck squamous cell carcinoma. Pathol Res Int 2013:502197
41. Supsavhad W, Dirksen WP, Martin CK, Rosol TJ (2016) Animal models of head and neck squamous cell carcinoma. Vet J 210:7–16
42. Bilgic O, Duda L, Sanchez MD, Lewis JR (2015) Feline oral squamous cell carcinoma: clinical manifestations and literature review. J Vet Dent 32(1):30–40
43. Stebbins KE, Morse CC, Goldschmidt MH (1989) Feline oral neoplasia: a ten-year survey. Vet Pathol 26(2):121–128
44. Vichai V, Kirtikara K (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1(3):1112–1116
45. Parkinson EI, Hergenrother PJ (2011) Runaway ROS as a selective anticancer strategy. Chem Med Chem 6(11):1957–1959
46. Huang X, Dong Y, Bey EA, Kilgore JA, Bair JS, Li LS, Patel M, Parkinson EI, Wang Y, Williams NS et al (2012) An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis. Cancer Res 72(12):3038–3047
47. Court MH (2013) Feline drug metabolism and disposition: pharmacokinetic evidence for species differences and molecular mechanisms. Vet Clin North Am Small Anim Pract 43(5):1039–1054
48. Booth DM (1990) Drug therapy in cats: mechanisms and avoidance of adverse drug reactions. J Am Vet Med Assoc 196(8):1297–1305
49. Hill AS, O'Neill S, Rogers QR, Christopher MM (2001) Antioxidant prevention of Heinz body formation and oxidative injury in cats. Am J Vet Res 62(3):370–37
50. Yang Y, Zhang Y, Wu Q, Cui X, Lin Z, Liu S, Chen L (2014) Clinical implications of high NQO1 expression in breast cancers. J Exp Clin Cancer Res 33:14
51. Lin L, Quin Y, Jin T, Liu S, Zhang S, Shen X, Lin Z (2014) Significance of NQO1 overexpression for prognostic evaluation of gastric adenocarcinoma. Exp Mol Pathol 96(2):200–205
52. Cui X, Jin T, Wang X, Jin G, Li Z, Lin L (2014) NAD(P)H:quinone oxideoreductase-1 overexpression predicts poor prognosis in small cell lung cancer. Oncol Rep 32(6):2589–2595
53. Ma Y, Kong J, Yan G, Ren X, Jin D, Jin T, Lin L, Lin Z (2014) NQO1 overexpression is associated with poor prognosis in squamous cell carcinoma of the uterine cervix. BMC Cancer 14:414
54. Li LS, Bey EA, Dong Y, Meng J, Patra B, Yan J, Xie XJ, Brekken RA, Barnett CC, Bornmann WG et al (2011) Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of beta-lapachone for pancreatic cancer therapy. Clin Cancer Res 17(2):275–285